(68)Ga-THP-PSMA : a PET imaging agent for prostate cancer offering rapid, room temperature, one-step kit-based radiolabeling
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 97763972
- Type
- D - Journal article
- DOI
-
10.2967/jnumed.117.191882
- Title of journal
- Journal of Nuclear Medicine
- Article number
- -
- First page
- 1270
- Volume
- 58
- Issue
- 8
- ISSN
- 0161-5505
- Open access status
- Not compliant
- Month of publication
- April
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
8
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- This paper builds on our development of tris(hydroxypyridinone) (THP) chelators (patent US9138495B2) for positron-emitter gallium-68. THP makes daily PET tracer radiosynthesis simpler and independent of costly infrastructure (cyclotron, hot cell, robotic synthesis etc.) by using a simple kit (patent US2018092996A1) and hence more widely available to patients. It describes preclinical development of prostate cancer tracer GalliProstTM, underpinning Phase 1 (https://doi.org/10.2967/jnumed.117.199554) and Phase 2 (EUDRACT 2017-005010-59/NCT03617588) trials and a new £6.3m EPSRC programme grant (EP/S032789/1). A Phase 3 trial is currently being registered. GalliprostTM has been commercialised by Theragnostics Ltd. (>£11m investment raised, Greg.Mullen@theragnostics.com) and already benefited >1200 patients (https://doi.org/10.1007/s11307-018-1160-8; https://doi.org/10.1007/s00259-019-04643-7).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -